Table 2.

Response to treatment with anti-TNF-α after 1 year in the four clusters

	Oligo N = 207	Poly N = 8	Hands N = 41	Feet N = 29
SJC 66	−1 (−3–0)	−10 ([−16]–[−2])	−7 ([−9]–[−1])	−11 ([−17]–[−6])
TJC 68	−1 (−4–0)	−6 ([−8]–[−3])	−5 ([−12]–[−1])	−11 ([−19]–[−5])
Current skin psoriasis	−1 (−2–0)	0 (0–0)	−1 (−2–0)	−1 (−2–0)
Patient global	−2 (−5–0)	−1 (−1–0)	−2 (−3–1)	−4 ([−7]–[−2])
Patient pain	−2 (−4–0)	−1 ([−2]–[−1])	−2 (−3–0)	−2 ([−6]–[−1])
HAQ-DI	0 (−1–0)	0 (0–0)	0 (−1–0)	0 (−1–0)
DLQI	−1 (−6–0)	No data	−1 ([−5]–[−1])	0 (0–0)
SF-36 PCS	5 (0–12)	5 (0–9)	7 (−1–9)	10 (1–13)
SF-36 MCS	1 (−2–5)	−2 (−9–4)	5 (0–9)	8 (0–11)
Physician global	−2 (−3–0)	−3 ([−4]–[−2])	−3 ([−5]–[−1])	−3 ([−6]–[−2])
CRP [mg/l]	0 (−6–0)	−2 (−15–0)	0 (−8–0)	−4 (−12–0)
ESR [mm/h]	−4 (−14–0)	−6 ([−16]–[−2])	−2 (−6–2)	−8 ([−31]–[−2])
DAS28 (CRP)	−1 (−2–0)	−1 (−2–0)	−1 (−2–0)	−2 (−2–0)

Median decrease and interquartile ranges (in parentheses) of different response parameters from start of anti-TNF-α treatment to 1 year later in the four clusters. None of the investigated response criteria showed significant change in a robust ANCOVA after multiple testing correction. SJC swollen joint count on the basis of 66 joints, TJC tender joint count on the basis of 68 joints, HAQ-DI health assessment questionnaire disability index, DLQI Dermatology Life Quality Index, SF-36 PCS/MCS short-form health survey physical/mental component score

CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 (CRP) disease activity score based on 28 joints and CRP